Is there Clinical Relevance for Therapies which Disrupt the Metastatic Cascade?

  • John D. Crissman
Part of the Developments in Oncology book series (DION, volume 22)


It is perplexing that while emphasis has been placed on the study of factors involved in carcinogenesis and treatment of established cancers, less effort is spent on the study of invasion and metastasis (1). Obviously, it is this element of the disease which is responsible for the majority of the morbidity and mortality of malignant cancer. “Is there clinical relevance for therapies which disrupt the metastatic cascade?” This is an intriguing question and addresses an area of clinical oncology which has not been a popular area for research. A wealth of biological and clinical information is available regarding carcinogenesis and, more recently, chemoprevention of neoplastic transformation. Research in cancer treatment has generated a vast body of knowledge dealing with the ablation of cancers once they are established. There are limited efforts in clinical investigation to develop therapies that have the potential for altering the metastatic cascade; most of these studies concentrate on aspects of the coagulation or fibrinolysis scheme. Coagulation, platelet aggregation and other factors involved in hemostasis have been clearly incriminated as contributing to steps in the metastatic cascade, but the details of their involvement are not completely understood (2).


Regional Lymph Node Vascular Invasion Circulate Tumor Cell Fetal Lung Regional Lymph Node Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Salomon JC. Invasion Metastasis 1: 1–2 1981.Google Scholar
  2. 2.
    Cederholm-Williams SA. Invasion Metastasis 1: 85–98, 1981.PubMedGoogle Scholar
  3. 3.
    Sugarbaker EV. Am. J. Pathol. 97: 623–632, 1979.PubMedGoogle Scholar
  4. 4.
    Fisher B, Redmond C and Fisher ER. Cancer (Philadelphia) 46: 1009–1025, 1980.CrossRefGoogle Scholar
  5. 5.
    Hart IR and Fidler IJ. Rev. Biol. 55: 121–142, 1980.CrossRefGoogle Scholar
  6. 6.
    Folkman J, Merler E, Abernathy C and Williams G. J. Exp. Med. 133: 275–288, 1981.Google Scholar
  7. 7.
    Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF. Science 219: 983–985, 1983.PubMedCrossRefGoogle Scholar
  8. 8.
    Lane N, Goksel H, Salerno RA and Haagensen CD. Ann. Surg. 153: 483–498, 1961.PubMedCrossRefGoogle Scholar
  9. 9.
    Smart CR, Myers MH and Gloeckler LA. Cancer (Philadelphia) 41: 787–789, 1978.CrossRefGoogle Scholar
  10. 10.
    Weigand RA, Isenberg WM, Russo J, Brennan MJ and Rich MA. Cancer (Philadelphia) 50: 962–969, 1982.CrossRefGoogle Scholar
  11. 11.
    Friedell GH, Betts A and Sommer SC. Cancer (Philadelphia) 18: 164–166, 1965.CrossRefGoogle Scholar
  12. 12.
    Tsakraklides V, Olson P, Kersey JH and Good RA. Cancer (Philadelphia) 34: 1259–1267, 1974.CrossRefGoogle Scholar
  13. 13.
    Barlogie B, Drewinko B, Schumann J, Gohde W, Dosik G, Latreille J, Johnson DA and Freireich EJ. Am. J. Med. 69: 195–203, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    Meyer JS, Bauer WC and Rao BR. Lab. Invest. 39: 225–235, 1980.Google Scholar
  15. 15.
    Crissman JD, Liu WY, Gluckman J and Cummings G. Cancer (Philadelphia) (in press).Google Scholar
  16. 16.
    Nakadate T, Suzuki M and Sato H. Gann 70: 435–446, 1979.PubMedGoogle Scholar
  17. 17.
    Sloane BF, Dunn JR and Honn KV. Science 212: 1151–1153, 1981.PubMedCrossRefGoogle Scholar
  18. 18.
    Hasimoto K, Yaminishi Y, Maeyen E, Dabbous MK and Kanzaki T. Cancer Res. 33: 2790–2801, 1973.Google Scholar
  19. 19.
    Poole AR, Tiltman KJ, Recklies AD and Stoker TAM. Nature (London) 273: 545–547, 1978.CrossRefGoogle Scholar
  20. 20.
    Liotta LA, Kleinerraan J, Catanzaro P and Rynbrandt D.J. Natl. Cancer Inst. 58: 1427–1431, 1977.Google Scholar
  21. 21.
    Sylven B. In: Biochemical and Enzymatic Factors Involved in Cellular Detachment in Chemotherapy of Cancer Dissemination and Metastasis (Eds. Garattini J and Franchi G), Raven Press, New York, pp. 129–137, 1973.Google Scholar
  22. 22.
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S. Nature (London) 204: 67–68, 1980.CrossRefGoogle Scholar
  23. 23.
    Sloane BF, Honn KV, Sadler JG, Turner WA, Kimpson JJ and Taylor JD. Cancer Res. 42: 980–986, 1982.PubMedGoogle Scholar
  24. 24.
    Salsbury AJ. Cancer Treat. Rev. 2: 55–72, 1975.PubMedCrossRefGoogle Scholar
  25. 25.
    Liotta LA, Kleinerman J and Saidel GM. Cancer Res. 34: 997–1004, 1974.PubMedGoogle Scholar
  26. 26.
    Engell HC. Acta Chir. Scand. Suppl. 201: 1–70, 1955.PubMedGoogle Scholar
  27. 27.
    Weiss L, Mayhew E, Rapp DG and Holmes JC. Br. J. Cancer 45: 44–53, 1982.PubMedCrossRefGoogle Scholar
  28. 28.
    Brown CE and Warren S. Surg. Gynecol. Obstet. 66: 611–621, 1938.Google Scholar
  29. 29.
    Engell HC. Ann. Surg. 149: 457–461, 1959.PubMedCrossRefGoogle Scholar
  30. 30.
    Griffiths JD and Salsbury AJ. Circulating Cancer Cells, Charles C. Thomas Publisher, Springfield, IL, 1965.Google Scholar
  31. 31.
    Fisher ER and Fisher B. Cancer (Philadelphia) 12: 926–932, 1959.CrossRefGoogle Scholar
  32. 32.
    Zeidman I, McCutcheon M and Coman DR. Cancer Res. 10: 357–361, 1950.PubMedGoogle Scholar
  33. 33.
    Fidler IJ. Cancer Res. 34: 491–498, 1974.PubMedGoogle Scholar
  34. 34.
    Liotta L, Kleinerraan J and GM. Cancer Res. 36: 889–894, 1976.PubMedGoogle Scholar
  35. 35.
    Watanabe S. Cancer (Philadelphia) 7: 215–223, 1954.CrossRefGoogle Scholar
  36. 36.
    Gasic GJ, Gasic TB, Galanti N, Johnson T and Murphy S. Int. J. Cancer 11: 704–718, 1973.Google Scholar
  37. 37.
    Nicolson GL and Winkelhake JL. Nature (London) 255: 230–232, 1975.CrossRefGoogle Scholar
  38. 38.
    Warren BA. J. Med. 4: 150–177, 1973.PubMedGoogle Scholar
  39. 39.
    Riggins RS and Ketcham AS. J. Surg. Res. 5: 200–206, 1965.PubMedCrossRefGoogle Scholar
  40. 40.
    Jonasson OL, Long S, Robers E, McGrew E and McDonald JH. J. Urol. 85: 1–12, 1961.Google Scholar
  41. 41.
    Butler TP and Gullino PM. Cancer Res. 35: 512–516, 1975.PubMedGoogle Scholar
  42. 42.
    Roberts E, Jonasson O, Long S, McGrew EA, McGrath R and Cole WH. Cancer (Philadelphia) 15: 232–240, 1962.CrossRefGoogle Scholar
  43. 43.
    Turnbull RB, Kyle K, Watson FR and Spratt J. Ann. Surg. 166: 420–425, 1967.PubMedCrossRefGoogle Scholar
  44. 44.
    Baker D, Elkon D, Lim M, Constable W and Wanebo H. Cancer (Philadelphia) 48: 2394–2398, 1981.CrossRefGoogle Scholar
  45. 45.
    Ketcham AS, Ryan JJ and Wexler H. Ann. Surg. 169: 297–299, 1975.CrossRefGoogle Scholar
  46. 46.
    Hoover HG and Ketcham AS. Am. J. Surg. 130: 405–411, 1975.PubMedCrossRefGoogle Scholar
  47. 47.
    Bross IDJ, Viadana E and Pickren J. J. Chronic Dis. 28: 149–159, 1975.PubMedCrossRefGoogle Scholar
  48. 48.
    Kinsey DL. Cancer (Philadelphia) 11: 674–676, 1960.CrossRefGoogle Scholar
  49. 49.
    Poste G, Doll J, Brown AE, Tzeng J and Zeidman I. Cancer Res. 42: 2770–2778, 1982.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • John D. Crissman

There are no affiliations available

Personalised recommendations